News in the classification of WHO 2022 bladder tumors

Area of Science:

• Uropathology
• Oncology
• Molecular diagnostics

Background:

• The World Health Organization (WHO) Classification of Tumors series is periodically updated to reflect advances in cancer diagnosis and treatment.
• Significant advancements in molecular data and therapeutic approaches for urological cancers have occurred since the previous edition.
• Morphology has traditionally been the basis for tumor classification, but molecular insights are increasingly important.

Purpose of the Study:

• To summarize the key updates in the fifth edition of the WHO Classification of Tumors of the Urinary System and Male Genital Organs.
• To highlight the integration of molecular data and new therapeutic modalities in the classification and management of urological neoplasms.
• To provide insights into emerging concepts such as the molecular classification of urothelial carcinomas and immunotherapy.

Main Methods:

• Review and synthesis of the information presented in the fifth edition of the WHO Classification of Tumors of the Urinary System and Male Genital Organs.
• Analysis of new classifications, grading systems, and diagnostic criteria for urinary tract tumors.
• Examination of the role of molecular pathology and emerging therapeutic strategies in urological cancer management.

Main Results:

• The fifth edition introduces updated classifications for various urinary and male genital tract tumors.
• New insights are provided on the grading of non-invasive and invasive urothelial carcinomas, including precursor lesions.
• The classification acknowledges the diversity of morphological appearances and lineage of differentiation in urothelial carcinomas.

Conclusions:

• The 2022 WHO Classification represents a significant update, integrating morphological and molecular findings in urological tumor classification.
• Advances in immunotherapy and molecular diagnostics are shaping the management of selected urological neoplasms.
• Further research is needed to fully integrate these advances into routine pathology practice and patient care.